» Articles » PMID: 28606711

Impact of Atopic Dermatitis on Health-related Quality of Life and Productivity in Adults in the United States: An Analysis Using the National Health and Wellness Survey

Overview
Specialty Dermatology
Date 2017 Jun 14
PMID 28606711
Citations 81
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Given its public health impact, there is need for broad and representative data on the humanistic burden of atopic dermatitis (AD).

Objective: To establish the humanistic burden of AD in US adults.

Methods: Data were from the 2013 US National Health and Wellness Survey; AD self-reports were propensity-matched with non-AD controls and with psoriasis controls. Bivariate analyses were conducted on burden outcomes between the AD and control groups.

Results: Demographics and baseline characteristics were comparable between matched groups. Subjects with AD (n = 349) versus non-AD controls (n = 698) had significantly higher rates of anxiety, depression, and sleep disorders (29.8%, 31.2%, and 33.2% vs 16.1%, 17.3%, and 19.2%, respectively [all P < .001]); a lower Short Form-36 v2 mental component summary score (44.5 vs 48.0, respectively [P < .001]); a lower physical component summary score (47.6 vs 49.5, respectively [P = .004]), and lower health utilities (0.67 vs 0.72, respectively [P < .001]) in addition to a higher work absenteeism rate (9.9% vs 3.6%, respectively [P < .001]) and activity impairment rate (33.6% vs 25.2%, respectively [P < .001]). Subjects with AD and psoriasis controls (n = 260 each) showed similar impairment in health-related quality of life and productivity.

Limitations: Data were self-reported.

Conclusion: AD is associated with a substantial humanistic burden that is similar in magnitude to that of psoriasis, which is also recognized for its debilitating symptoms, indicating the need for more effective treatments for AD.

Citing Articles

Burden of mild and moderate atopic dermatitis in adults: results from a real-world study in the United States.

Silverberg J, Anderson P, Cappelleri J, Piercy J, Levenberg M, Myers D Arch Dermatol Res. 2025; 317(1):556.

PMID: 40072609 PMC: 11903610. DOI: 10.1007/s00403-025-03910-y.


One-Year Insights into the GLOBOSTAD Multinational Prospective Observational Study of Patients Receiving Dupilumab for Atopic Dermatitis.

Calzavara-Pinton P, Chu C, Lapeere H, Rossi M, Ferrucci S, Chung W Adv Ther. 2024; 42(2):720-733.

PMID: 39621227 PMC: 11787152. DOI: 10.1007/s12325-024-03049-8.


Atopic Dermatitis-Related Problems in Daily Life, Goals of Therapy and Deciding Factors for Systemic Therapy: A Review.

Lugovic-Mihic L, Barac E, Tomasevic R, Parac E, Zanze L, Ljevar A Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598368 PMC: 11597550. DOI: 10.3390/ph17111455.


Unveiling the Impact of Moderate and Severe Atopic Dermatitis: Insights on Burden, Clinical Characteristics, and Healthcare Resource Utilization in Adult Greek Patients from the APOLO Cross-Sectional Study.

Stratigos A, Chasapi V, Katoulis A, Vakirlis E, Psarros F, Georgiou S J Clin Med. 2024; 13(21).

PMID: 39518471 PMC: 11546607. DOI: 10.3390/jcm13216327.


Unmet Medical Needs and Early Referral of Pediatric Atopic Dermatitis: An Expert Modified Delphi Consensus from Saudi Arabia.

Alradaddi A, Al Twaim A, Abu-Aliat A, Al-Atass K, Alogayell L, Aldayil M Dermatol Res Pract. 2024; 2022:5636903.

PMID: 39444785 PMC: 11496595. DOI: 10.1155/2022/5636903.